Jazz Pharmaceuticals is a biopharmaceutical company. Co.'s products are: Xyrem®, which is for the treatment of both cataplexy and excessive daytime sleepiness (EDS), in both adult and pediatric patients with narcolepsy; Sunosi®, which improves wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; Defitelio®, which treats adult and pediatric patients with hepatic veno-occlusive disease; Erwinaze®, which is a treatment for patients with acute lymphoblastic leukemia; and Vyxeos®, which is a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. The JAZZ stock yearly return is shown above.
The yearly return on the JAZZ stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the JAZZ annual return calculation with any dividends reinvested as applicable (on ex-dates).
|